Plenary Session - inactive due to federal service
420 episodes — Page 7 of 9

2.51 BONUS! Clinical Trials Part 3
EThis BONUS lecture was a talk given to the Hematology/Oncology fellows at Oregon Health & Science University. It's part three of a three-part series on clinical trials. Back us on Patreon! www.patreon.com/plenarysession

2.50 Neil Ferguson, Ending Lockdown, & Updates on COVID-19 Management with Dr. Benjamin Singer
EThis week's topic is all things COVID-19 -- we discuss the viral scandal of British epidemiologist Neil Ferguson's actions and how it reflects (or doesn't) on his work, we talk about the nuances of how to end lockdowns, and we bring back Dr. Benjamin Singer, a pulmonary and critical care physician at Northwestern University, to address updates in the ICU management of COVID-19. Invisible Pandemic: doi.org/10.1016/S0140-6736(20)31035-7 Back us on Patreon! www.patreon.com/plenarysession

2.49 COVID-19 Contrarians, Remdesivir, & Book Club on "Malignant" with OHSU HemOnc Fellows
EThis week we begin with a monologue on the recent controversy surrounding Dr. John Ioannidis's published opinions on the COVID-19 pandemic. We end with a group discussion with Oregon Health & Science University's Hematology/Oncology fellows on our host's, Vinay Prasad's, new book "Malignant: How Bad Policy and Bad Evidence Harm People with Cancer." Expressing different views on COVID-19: https://www.statnews.com/2020/04/27/hear-scientists-different-views-covid-19-dont-attack-them/ Malignant: www.amazon.com/Malignant-Policy-Evidence-People-Cancer/dp/1421437635 Back us on Patreon! www.patreon.com/plenarysession

2.48 BONUS! Introduction to Malignant: How Bad Policy and Bad Evidence Harm People with Cancer
EThis week we have a BONUS episode for you! As a teaser to the forthcoming audiobook of "Malignant: How Bad Policy and Bad Evidence Harm People with Cancer" by Dr. Vinay Prasad (our host), Audrey Tran and Ian Straehley have set the introduction of the book to music they composed and arranged themselves. You can buy the print version of Malignant from Amazon: https://www.amazon.com/Malignant-Policy-Evidence-People-Cancer-dp-1421437635/dp/1421437635/ Back us on Patreon! www.patreon.com/plenarysession

2.47 Remdesivir, Cloth Masks, & Incentives for COVID-19 Drug Development with Dr. Ameet Sarpatwari
EThis week we start with an in-depth monologue on various new developments surrounding COVID-19, specifically the new study in NEJM on the compassionate use of remdesivir as well as the CDC's advice for the general public to wear cloth masks. We end with an interview with Dr. Ameet Sarpatwari of Harvard Medical School on how to create a more effective pharmaceutical system, the CREATES Act of 2019, developing fair and equitable drugs to treat COVID-19, and how to create a just system that balances the need for innovation with the need for access. Dr. Ameet Sarpatwari is the Assistant Director of PORTAL. Compassionate Use of Remdesivir: doi.org/10.1056/NEJMoa2007016 U.S. Gene Therapy Trials: doi.org/10.1001/jama.2019.22214 NIH Fair Pricing Condition: doi.org/10.7326/M19-2576 Back us on Patreon! www.patreon.com/plenarysession

2.46 Psychology Unearthed by COVID-19 Precautions & Polygenic Risk Score with Dr. Venk Murthy
EThis week we have a far-reaching monologue on COVID-19 and how people are reacting to the public health recommendations concerning COVID-19 (such as cancelling conferences and school, maintaining 6+ feet of distance, wearing cloth masks). We end with an insightful interview with Dr. Venk Murthy on polygenic risk score and, at the end, a bit about how the world of science is failing to combat hype. Back us on Patreon! www.patreon.com/plenarysession

2.45 Viral Spread of SARS-CoV-2, Rationing Resources, "Evidence Fiasco", & Classical Hematology Chat
EThis week we discuss several recent articles on the novel coronavirus (SARS-CoV-2) and COVID-19, specifically Dr. Siddhartha Mukherjee's article on the history and science of humanity's history with viruses, Dr. Ezekiel Emanuel's essay on how to fairly allocate dwindling medical resources during this global pandemic, and Dr. John Ioannidis's article on the "evidence fiasco" that has been our response to COVID-19. We end the episode with a Classical Hematology Chat with Drs. Sven Olson and Joseph Shatzel. Dr. Mukherjee's article: https://www.newyorker.com/magazine/2020/04/06/how-does-the-coronavirus-behave-inside-a-patient Allocation of Medical Resources: doi.org/10.1056/NEJMsb2005114 Dr. Ioannidis's article: https://www.statnews.com/2020/03/17/a-fiasco-in-the-making-as-the-coronavirus-pandemic-takes-hold-we-are-making-decisions-without-reliable-data/ Back us on Patreon! www.patreon.com/plenarysession

2.44 ICU Management of COVID-19 with Dr. Benjamin Singer
EThis week we discuss management of COVID-19 in the intensive care unit with Dr. Benjamin Singer, a pulmonary and critical care physician at Northwestern University. We discuss medications, PPE, ventilators, and more! Back us on Patreon! www.patreon.com/plenarysession

2.43 BONUS! Novel Coronavirus and the COVID-19 Response in Oregon with Dr. John Townes
EThis bonus episode is an interview from March 16, 2020 with Dr. John Townes, the Interim Head for the Division of Infectious Disease and the Medical Director for Infection Prevention and Control here at Oregon Health & Science University. We talk about the novel coronavirus and how healthcare professionals are responding to the COVID-19 pandemic, with a focus on Oregon. Back us on Patreon! www.patreon.com/plenarysession

2.42 Quality-of-Life Measurement in Oncology, KnowYourTumor, & Question of the Week
EThis week we discuss two recent papers -- one we praise, one we condemn -- and then we turn to a question of the week with medical student Audrey Tran on self-improvement and "refining conviction". The first paper is titled "Patient Experience Captured by Quality-of-Life Measurement in Oncology Clinical Trials" and the second is titled "Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial". Quality of Life Measurement: doi.org/10.1001/jamanetworkopen.2020.0363 KnowYourTumor: doi.org/10.1016/S1470-2045(20)30074-7 Vinay's new book, Malignant: www.amazon.com/Malignant-Policy-…cer/dp/1421437635 Back us on Patreon! www.patreon.com/plenarysession

2.41 BONUS! Clinical Trials Part 2: Crossover and Control Arms
EThis BONUS lecture was a talk given to the Hematology/Oncology fellows here at Oregon Health & Science University. It's part two of a three-part series on clinical trials. This talk is on clinical trial design, specifically crossover and control arms. Back us on Patreon! www.patreon.com/plenarysession

2.40 BEACON part 2, NALA, & Molecular Pathology and Next-Generation Sequencing with Dr. David Carr
EThis week we revisit BEACON! The authors of the BEACON study have responded to the Letter to the Editor our host Dr. Vinay Prasad submitted to the New England Journal of Medicine, and we share our thoughts on what they said. We then turn to the FDA's recent approval of neratinib in combination with capecitabine for HER2-positive breast cancer, based on the phase III NALA trial. Finally, we interview Dr. David Carr, a Molecular Pathology Fellow at UC San Diego, on his work in general and, specifically, next-generation sequencing. BEACON Letters to the Editor: www.nejm.org/doi/full/10.1056/NEJMoa1908075#article_letters NALA: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neratinib-metastatic-her2-positive-breast-cancer Vinay's new book, Malignant: www.amazon.com/Malignant-Policy-…cer/dp/1421437635 Back us on Patreon! www.patreon.com/plenarysession

2.39 Effectiveness of Newer-Generation Antidepressants with Dr. Michael Hengartner
EOur guest this week is Dr. Michael Hengartner of the Zurich University of Applied Sciences. We interview him on his work studying the long-term consequences and effectiveness of newer-generation antidepressants - specifically focusing on selective serotonin reuptake inhibitors (SSRIs). Back us on Patreon! www.patreon.com/plenarysession

2.38 KEYNOTE-048, Academic Currency, & Trials in Low/Mid-Income Countries with Dr. Bishal Gyawali
EWe start this episode by diving deep into KEYNOTE-048, the randomized, open-label, phase 3 study of pembrolizumab alone or with chemotherapy v.s. cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC). We transition from there to a continued discussion on careerism in academia and how the motivation behind publishing papers should always stem from the drive to disseminate information, not from the drive to advance your own career. We end the episode with an interview with Dr. Bishal Gyawali of Queen's University in Kingston, Canada on his recent paper out in Nature Cancer on global oncology. Specifically, Dr. Gyawali addresses the need for conducting cancer clinical trials in low- and middle-income countries. KEYNOTE-048: doi.org/10.1016/S0140-6736(19)32591-7 Opportunities for Cancer Clinical Trials in LMIC: doi.org/10.1038/s43018-020-0030-x Vinay's new book, Malignant: www.amazon.com/Malignant-Policy-…cer/dp/1421437635 Back us on Patreon! www.patreon.com/plenarysession

2.37 Careerism, Presenting Abstracts, Twitter and the K-Index, & Classical Hematology Chat
EWe have a full slate for you this week! We discuss careerism in medicine, presenting abstracts at conferences, #MedTwitter, and Dr. Califf's opinions on the K-Index. We conclude the episode with our first-ever Classical Hematology Chat, featuring our host Dr. Vinay Prasad, Dr. Sven Olson, and Dr. Joseph Shatzel. The chat is on sickle cell disease. "A Perspective on the K-Index": doi.org/10.1016/j.jaccas.2020.01.003 Back us on Patreon! www.patreon.com/plenarysession

2.36 Thought Leaders, NELSON, & Reliance on P Values in Cancer Trials with Dr. Sam Rubinstein
EThis week we discuss the concept of "thought leaders" and we examine the conclusions about volume CT screening for lung cancer from the NELSON trial. We end with an interview with Dr. Sam Rubinstein, a hematology/oncology fellow at Vanderbilt University Medical Center, on his new paper published in JAMA Network Open titled "Indication of Measures of Uncertainty for Statistical Significance in Abstracts of Published Oncology Trials: A Systematic Review and Meta-analysis". NELSON: doi.org/10.1056/NEJMoa1911793 Measures of Uncertainty: doi.org/10.1001/jamanetworkopen.2019.17530 Back us on Patreon! www.patreon.com/plenarysession

2.35 BONUS! How to Keep Up with the New Information in Medicine
EThis BONUS episode is the recording of a lecture given to medical students titled "How to Keep Up with the New Information in Medicine." It's a primer on the steps healthcare professionals need to take in order to keep abreast of the latest medical findings. Vinay's new book, Malignant: www.amazon.com/Malignant-Policy-…cer/dp/1421437635 Back us on Patreon! www.patreon.com/plenarysession

2.34 Red Light, Pola for DLBCL, Hem/Onc Question of the Week, & TAILORx with Dr. Ali Khaki
EWe have a variety of topics for you this week! We tackle red light therapy, polatuzumab olatuzumab vedotin in relapsed or refractory diffuse large b-cell lymphoma; we have a hematology/oncology question of the week from Dr. Emerson Chen of OHSU; and we sit down with Dr. Ali Khaki of the Fred Hutchinson Cancer Research Center to discuss his recent paper critiquing TAILORx. Pola for DLBCL: doi.org/10.1200/JCO.19.00172 Financial COI on Twitter: doi.org/10.1001/jamainternmed.2016.8467 Ignoring Valuable Data: doi.org/10.6004/jnccn.2019.7363 Back us on Patreon! www.patreon.com/plenarysession

2.33 Olaparib and POLO & the Classical Fallacies of Cancer Screening with Dr. H Gilbert Welch
EThis week we're treating you to a recording of the Grand Rounds lecture on overdiagnosis and cancer screening that Dr. H Gilbert Welch gave at Oregon Health & Science University on October 30, 2019. Before the lecture, we take a moment to reiterate with renewed vigor our distaste for the POLO trial (first discussed in episode 1.64). POLO: doi.org/10.1056/NEJMoa1903387 Back us on Patreon! www.patreon.com/plenarysession

2.32 BONUS! Clinical Trials Part 1: Thinking Better About Cancer Medicine
EThis BONUS lecture was a talk given to the Hematology/Oncology fellows here at Oregon Health & Science University. It's part one of a three-part series on clinical trials, titled "Thinking Better About Cancer Medicine". Back us on Patreon! www.patreon.com/plenarysession

2.31 Listener Questions, Responsibility of Reviewers, & Duration of Response with Dr. Bishal Gyawali
EThis week we answer a few questions: the first is from Patreon backer, Harry Hong, on Kaplan-Meier curves. The second is from a student at Mount Sinai Medical School who reached out with some ethical questions they had after the ASH annual meeting on the obligations and responsibilities of peer reviewers. Finally, we end the episode with an interview with Dr. Bishal Gyawali of Queens University in Kingston, Ontario, Canada on his new paper out today in the Journal of the National Comprehensive Cancer Network titled "Response Rates and Durations of Response for Biomarker-Based Cancer Drugs in Nonrandomized Versus Randomized Trials". Durations of Response: doi.org/10.6004/jnccn.2019.7345 Vinay's new book, Malignant: www.amazon.com/Malignant-Policy-…cer/dp/1421437635 Back us on Patreon! www.patreon.com/plenarysession

2.30 Questions from a Medical Student & Epidemiology with Dr. Ellie Murray
EThis week we return to our discussion of going after soft targets vs hard targets, but this time with a focus on how it applies to building a burgeoning career in medicine, in our segment Questions from a Medical Student with Audrey Tran. We end this week's episode with a far-reaching interview with Dr. Ellie Murray (most people know her as Epi Ellie on Twitter and as the co-host of the podcast Casual Inference) on all things epidemiology. Check out Dr. Murray's excellent podcast here: https://casualinfer.libsyn.com/ Back us on Patreon! www.patreon.com/plenarysession

2.29 Time from Diagnosis to Treatment in AML and Real-World Data with Dr. Sherrie Aspinall
EThis week we wonder incredulously how this abstract from ASH titled "Time from diagnosis to treatment does not affect outcome in intensively treated patients with newly diagnosed acute myeloid leukemia" was selected as one of the top abstracts from the conference. In the second half of the episode we interview Dr. Sherrie Aspinall of the Veterans Administration on how to use real-world data. Her new paper is titled "Use of targeted therapies for advanced renal cell carcinoma in the Veterans Health Administration". Time from diagnosis to treatment in AML: https://ashpublications.org/blood/article-lookup/doi/10.1182/blood-2019-123717 Targeted therapies for advanced RCC: doi.org/10.1002/cam4.2531 Vinay's new book, Malignant: www.amazon.com/Malignant-Policy-…cer/dp/1421437635 Back us on Patreon! www.patreon.com/plenarysession

2.28 Trastuzumab in Later Lines of Therapy for HER2+ Breast Cancer, Kaplan-Meier Curves, & Patreon
EWe're back in Plenary Session HQ! We have multiple topics for you this week. We cover the use of trastuzumab in later lines of therapy for HER2+ metastatic breast cancer, we take a listener question on Kaplan-Meier curves, and we talk a little about Patreon. Malignant: www.amazon.com/Malignant-Policy-Evidence-People-Cancer/dp/1421437635 Back us on Patreon! www.patreon.com/plenarysession

2.27 BONUS! Use of Bone-Modifying Agents Among Medicare Beneficiaries with MM with Dr. Arjun Gupta
EThis BONUS episode is an interview with Dr. Arjun Gupta, a second-year hem/onc fellow at Johns Hopkins University, on his new paper out TODAY in JAMA Oncology titled ''Use of Bone-modifying Agents among Medicare Beneficiaries with Multiple Myeloma''. Use of bone-modifying agents: doi.org/10.1001/jamaoncol.2019.5426 Back us on Patreon! www.patreon.com/plenarysession

2.26 Questions of the Week: Hematology/Oncology, USMLE Step 2 CK, & a bonus Hematology/Oncology
EThis is the last week of pre-recorded episodes -- we'll be back next week with a fresh, hard-hitting monologue. In the meantime, we have three questions of the week for you. Two are inspired by the hematology/oncology boards and are presented by Dr. Sven Olson. Between the two, we have one from Ian Straehely that's inspired by the USMLE Step 2 CK. Back us on Patreon! www.patreon.com/plenarysession

2.25 Questions of the Week: Hematology/Oncology, the USMLE Step 2 CK, & One From a Med Student
EOur host is still out of town, but don't worry -- we have some questions of the week to tide you over. The first is inspired by the hematology/oncology boards, presented by Dr. Sven Olson; the second is inspired by the USMLE Step 2 CK, presented by Ian Straehley; and the third is from Audrey Tran, inspired by her experiences as a med student. Back us on Patreon! www.patreon.com/plenarysession

2.24 Questions of the Week: the USMLE Step 2 CK, Hematology/Oncology, & One From a Med Student
EThis week our host is still in Australia, but we have some questions of the week saved for you! The first is inspired by the USMLE Step 2 CK, presented by Ian Straehley; the second is inspired by the hematology/oncology boards, presented by Dr. Sven Olson; and the third is from Audrey Tran, inspired by her experiences as a med student. Back us on Patreon! www.patreon.com/plenarysession

2.23 Question of the Week & Ethics and Inefficiencies of Clinical Trials with Dr. Jonathan Kimmelman
EFirst up this week is Question of the Week inspired by the Hematology/Oncology boards, with Dr. Sven Olson. No monologue on current trials this week because our host is still in Australia, so we conclude the episode with an interview with Dr. Jonathan Kimmelman of McGill University on his extensive work in research ethics, studying the most important issue in cancer medicine today: the risk-benefit of clinical trials and how best to spare patients from the burdens of creating a new drug. Review of Sunitinib: doi.org/10.1093/jnci/djv292 Benefit, Burden, and Impact: doi.org/10.1177/1740774519873883 Back us on Patreon! www.patreon.com/plenarysession

2.22 Question of the Week & EMR, Talking to Patients, and Being a Doctor with Dr. Robert Hirschtick
EThis week we have a question of the week from Ian Straehley, inspired by the USMLE Step 2 CK, as well as an interview with Dr. Robert Hirschtick of Northwestern University on what it means to be a doctor, how you should think as a physician, and his many popular pieces published in journals like JAMA. "Copy-and-Paste": doi.org/10.1001/jama.295.20.2335 "Extremities": doi.org/10.1001/jama.300.10.1125 "The Quick Physical Exam": doi.org/10.1001/jama.2016.8182 Robiewon on YouTube: www.youtube.com/channel/UC2Ki7Zbo2VCGQAYinsJhU3w "You Did Not Teach Me What You Thought You Did": doi.org/10.1001/jama.2019.15849 Back us on Patreon! www.patreon.com/plenarysession

2.21 Aiming for the Hard Targets & Harm From Screening and Overdiagnosis with Dr. H Gilbert Welch
EWe begin this week's episode by addressing a listener's feedback to our discussion of smoldering multiple myeloma. We then expand on our critique of 'going after the soft targets' (criticizing studies that fall apart with little resistance) by elucidating how to identify and go after hard targets and why it's so important that you do. Finally, we launch into an interview with Dr. H Gilbert Welch that explores his tremendous body of work on the preventable harm that comes from too generous a hand with novel diagnostic advances. Back us on Patreon! www.patreon.com/plenarysession

2.20 "Courageous Skeptics", Lenalidomide, QOTW, and a Political Conversation with Dr. Andy Saultz
EWe begin this week's episode with a thoughtful discussion of the internet's "courageous skeptics". Then, after lamenting the way in which the recent study "Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma" was conducted, we end with an interview with Dr. Andy Saultz on his ongoing campaign for Oregon state representative. We break up the interview with a couple Hem/Onc boards questions of the week from Dr. Emerson Chen. Lenalidomide in Smoldering Multiple Myeloma: doi.org/10.1200/JCO.19.01740 Back us on Patreon! www.patreon.com/plenarysession

2.19 Remembering Dr. Bernard Fisher & Self-Diagnosis with Dr. Mark Lewis
EThis week we give a short monologue on the late Dr. Bernard Fisher's legacy in the field of oncology, and then dive into a far-ranging interview with Dr. Mark Lewis of Intermountain Healthcare on his career, his family, and diagnosing himself with MEN1 syndrome. Dr. Fisher's obituary in the New York Times: https://www.nytimes.com/2019/10/19/science/dr-bernard-fisher-dead.html Back us on Patreon! www.patreon.com/plenarysession

2.18 Questions of the Week, Talking About Toxicity, ASCO Guidelines Authors' COI with Dr. Eitan Amir
EThis week we begin with a critique of the recent perspective article in the New England Journal of Medicine, titled "Talking about Toxicity — 'What We’ve Got Here Is a Failure to Communicate'". After that we interview Dr. Eitan Amir on his paper on undisclosed conflicts of interest among authors of ASCO guidelines. Interspersed between segments of the interview, we invite guest Dr. Sven Olson on to offer a correction to a recent Hem/Onc boards question of the week on Lynch Syndrome (original question posed in episode 2.11) and we invite Ian Straehley on for a question of the week inspired by the USMLE Step 2 CK. Talking about toxicity: doi.org/10.1056/NEJMp1908310 COI among authors of ASCO guidelines: doi.org/10.1002/cncr.32408 Transparency in medicine: doi.org/10.1002/cncr.32407 Back us on Patreon! www.patreon.com/plenarysession

2.17 Questions of the Week, BEACON, & Use of Subacuate Rehab with Dr. Jonathan Yeh
EWe start this week's episode with a quick breakdown of why the recent BEACON trial is "the worst trial" host VP has ever read. After that, we have two questions of the week: one from medical student Audrey Tran, and one inspired by the Hem/Onc boards from Dr. Sven Olson. We end with an interview with Dr. Jonathan Yeh of Johns Hopkins University School of Medicine on his recent paper: "Has There Been a Shift in Use of Subacute Rehabilitation Instead of Hospice Referral Since Immunotherapy Has Become Available?". BEACON: doi.org/10.1056/NEJMoa1908075 Subacute Rehabilitation: doi.org/10.1200/JOP.19.00044 Back us on Patreon! www.patreon.com/plenarysession

2.16 FLAURA & What Truly Matters in the Career of an Academic Physician with Dr. Vinay Prasad
EThis week we break down the limitations of the recent FLAURA trial and then we're back in the Plenary Session Mobile Command Unit! We have a special guest host, Dr. Christopher Booth of Queen's University in Kingston, Ontario, Canada. He and Dr. Bishal Gyawali, also of Queen's University, conduct a reverse interview with our usual host, Dr. Vinay Prasad of Oregon Health & Science University, on his career, the formation of Plenary Session, and what truly matters in the career of an academic physician. FLAURA: doi.org/10.1056/NEJMoa1713137 Price of an Anticancer Drug: doi.org/10.1001/jamainternmed.2017.3601 Simply Measurable or Clinically Meaningful? doi.org/10.1200/jco.2011.38.7571 The Emperor Has No Clothes: doi.org/10.1200/JCO.2008.19.5594 Making Room in Oncology: www.medscape.com/viewarticle/917628 Back us on Patreon! www.patreon.com/plenarysession

2.15 Bonus! The Value of Progression-Free Survival as a Treatment Endpoint with Dr. Michael Raphael
EThis BONUS episode is an interview with Dr. Michael Raphael of Sunnybrook Health Sciences Centre in Toronto, Ontario on his new paper out today in JAMA Oncology: "The value of progression-free survival as a treatment endpoint among patients with advanced cancer: a systematic review and qualitative assessment of the literature". Value of PFS: https://jamanetwork.com/journals/jamaoncology/article-abstract/2751879 Back us on Patreon! www.patreon.com/plenarysession

2.14 Questions of the Week & Qualifications of a Fellowship Applicant with Dr. Jeremy Cetnar
EThis week we sit down with Dr. Jeremy Cetnar, director of the Oregon Health & Science University Hematology & Oncology Fellowship Program. In this far-ranging interview, we discuss what he is looking for when reviewing applications to the fellowship program. We also have two questions of the week: one from Dr. Derrick Tao, inspired by the MKSAP; and one from Dr. Sven Olson on hematology and oncology. Tweetorials: http://doi.org/10.1056/NEJMp1906790 Back us on Patreon! www.patreon.com/plenarysession

2.13 BONUS! RCTs Supporting Approvals of Cancer Drugs by EMA with Dr. Huseyin Naci
EOn this week's BONUS episode, we sit down with Dr. Huseyin Naci, Assistant Professor of Health Policy at the London School of Economics, to discuss his new paper that came out Wednesday (producer's edit: not "yesterday" as said in the podcast - apologies for the delay!) in the British Medical Journal. The paper's titled "Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis." RCTS Supporting Approvals: doi.org/10.1136/bmj.l5221 Back us on Patreon! patreon.com/plenarysession

2.12 Questions of the Week, Ethics of RCTs, & Transmission and Medical Overuse with Dr. Dan Morgan
EWe begin this week's episode by revisiting last week's topic on the ethics of randomized controlled trials (RCTs) to address some of the controversy stirred up by our episode. We transition from there to an interview with Dr. Dan Morgan of the University of Maryland School of Medicine on hospital transmission and medical overuse. We have two questions of the week, as well -- one from Ian Straehley, inspired by the USMLE Step 2 CK; and one from Audrey Tran, inspired by the life of a medical student. Back us on Patreon! www.patreon.com/plenarysession

2.11 Questions of the Week, When RCTs are Necessary, & AYA Oncology with Dr. Adam Duvall
EAfter a hiatus from our segment on reviewing recent trials, we return to discuss the need for randomized controlled trials (RCTs). In the wake of the 2019 World Conference on Lung Cancer, we focus on whether a phase III trial of selpercatinib (LOXO-292) in RET rearranged lung cancer is feasible, practical, and ethical. We also have two questions of the week in this episode -- one from Dr. Derrick Tao, inspired by the MKSAP; and one from Dr. Sven Olson on hematology and oncology -- as well as an interview with Dr. Adam Duvall of OHSU on his career in the field of adolescent and young adult (AYA) oncology. Back us on Patreon! patreon.com/plenarysession

2.10 Questions of the Week: the USMLE Step 2 CK, the MKSAP, & Hematology/Oncology
EWe have three questions for you this week: one from Ian Straehley, inspired by the USMLE Step 2 CK; one from Dr. Derrick Tao, inspired by the MKSAP; and one from Dr. Sven Olson on hematology and oncology. Back us on Patreon! www.patreon.com/plenarysession

2.09 Questions of the Week & Informed Consent in Clinical Trials with Dr. Lynn Jansen
EWe start this week with two Questions of the Week: the first is from Ian Straehley on the USMLE Step 2 CK, and the second is from Dr. Sven Olson on hematology/oncology. We end with an interview with Dr. Lynn Jansen of OHSU on the therapeutic misconception, optimism bias, and a deep discussion of the ethics of consenting patients for enrollment in early-phase clinical research trials. Back us on Patreon! www.patreon.com/plenarysession

2.08 Questions of the Week: the MKSAP, the USMLE Step 2 CK, & From a Med Student
EWe have three questions for you this week: one from Dr. Derrick Tao, inspired by the MKSAP; one from Ian Straehley, inspired by the USMLE Step 2 CK; and one from Audrey Tran, inspired by her journey through medical school. Back us on Patreon! www.patreon.com/plenarysession

2.07 Translational Research & Physical Examination Pet Peeves with Dr. Adam Cifu
EWe start this week's episode with a Question of the Week from medical student Audrey Tran on translational research and medical student training. Afterwards, we have an in-depth interview with Dr. Adam Cifu of the University of Chicago on his recent publication: "Physical Examination Pet Peeves". Pet Peeves: doi.org/10.4300/JGME-D-18-01063.1 Back us on Patreon! www.patreon.com/plenarysession

2.06 Heart Failure, Choosing a Specialty, & the Bayesian Approach with Dr. Frank Harrell
EWe're back with more questions of the week! Our first question, from Ian Straehley, is inspired by the USMLE Step 2 CK; our second question, from Audrey Tran, is on deciding on a medical specialty. We end the episode with an interview with Dr. Frank Harrell of Vanderbilt University on the Bayesian approach to statistical thinking. Back us on Patreon! www.patreon.com/plenarysession

2.05 Reup! Cancer Screening 101 with Dr. Adam Obley
EIn this REUP episode, we replay a section of our interview with Dr. Adam Obley of OHSU: a primer on cancer screening. This audio was first aired on episode 2.03. Not So Silver Lining: doi.org/10.1001/archinternmed.2011.73 Mammography Screening: Truth, Lies and Controversy: www.crcpress.com/Mammography-Screening-Truth-Lies-and-Controversy/Gotzsche/p/book/9781846195853 Back us on Patreon! www.patreon.com/plenarysession

2.04 Reup! Tumor-Treating Fields for Glioblastoma with Dr. Michael Hayes
EIn this REUP episode, we replay a section of our interview with Dr. Michael Hayes of Kaiser Permanente. This audio was first aired on episode 2.01. The interview is on the relationship between conflict of interest and editorial stance on tumor-treating fields for glioblastoma multiforme. TTF: doi.org/10.1016/j.jcpo.2019.100189 Back us on Patreon! www.patreon.com/plenarysession

2.03 Dr. Charles Moertel and the Modern Oncologist & Cancer Screening 101 with Dr. Adam Obley
EThis week we launch a new segment on Plenary Session: Question of the Week! We invite Dr. Sven Olson on to ask a sample hematology/oncology boards question and we invite Audrey Tran on to ask a question from a medical student. Before that, we talk about the legacy of Dr. Charles Moertel and how modern oncologists, in contrast, will be remembered. We end the episode with an interview with Dr. Adam Obley of OHSU -- his fourth appearance on the podcast! -- on cancer screening. Dr. Moertel's obituary: https://www.nytimes.com/1994/06/29/obituaries/charles-moertel-66-studied-treatment-and-cost-of-cancer.html Faith Lost, a Doctor Turns Bitter: https://www.latimes.com/archives/la-xpm-1993-09-12-mn-34516-story.html Not So Silver Lining: doi.org/10.1001/archinternmed.2011.73 Mammography Screening: Truth, Lies and Controversy: https://www.crcpress.com/Mammography-Screening-Truth-Lies-and-Controversy/Gotzsche/p/book/9781846195853 Back us on Patreon! www.patreon.com/plenarysession

2.02 BONUS! Improving Access to Prescription Drugs through Policy Change with Dr. Stacie Dusetzina
EThis BONUS episode is a recording of a lecture that Dr. Stacie Dusetzina of Vanderbilt University gave for grand rounds at OHSU on June 19, 2019. The lecture is on the cost of prescription drugs and out-of-pocket spending. Back us on Patreon! www.patreon.com/plenarysession